Micro-biopsie prostatique transrectale écho-guidée : notre expérience en milieu tropical sur 317 cas
DOI:
https://doi.org/10.55715/jaim.v15i3.526Keywords:
Prostate-Microbiopsy-Transrectal-Ultrasonography ; Prostate cancerAbstract
Introduction: Prostate cancer is the first cancer in men in Côte d’Ivoire. Transrectal US-guided microbiopsy is the part of the diagnosis and patient management.
Objective: present the results of our practice and determine any specificities.
Materials and methods: Transversal study over 3 years, including 93 patients. Examination carried out on a GE Logic 8 ultrasound machine, by the same operator with an 18-gauge needle mounted on a BARD system gun (according to international recommendations) and the samples sent to the pathological laboratories.
Results: the mean age of the patient was 63.18 years ± 7.84 years. The main reasons for consultation were high PSA (38.71%) and prostatic hypertrophy (32.26%). The mean PSA level was 63.72 ng/ml. The average prostate volume was 68.55 cc. The US showed a heterogeneous prostate (95%) and nodules (78%). Nodules were hypoechoic (78%) and located in the peripheral zone (66%). There was capsular effraction (56%), locoregional invasion (11%) and adenomegaly (8.06%). On average 8.53 biopsy samples were taken. All patients had local anesthesia of the neurovascular strips with injectable lidocaine diluted to 2%. Histology showed 45.16% adenocarcinomas (mean age 65.97 years), a Gleason score of 7 and 9 (30.95%), perineural sheathing (16.67%). In 51.72% of cases the samples were positive at 90-100% and bilaterally (60%) with an average tumor size of 6 mm ± 4.01mm.
Conclusion:
Our study showed that prostate cancer had a high Gleason score and tumor volume with a significant proportion of positive cores, predictive of extra prostatic disease and a high rate of tumor recurrence.
RÉSUMÉ
Introduction : Le cancer de la prostate occupe en Côte d’Ivoire le premier rang chez l’homme. La microbiopsie transrectale échoguidée fait partie du protocole de diagnostic et de prise en charge.
Objectifs : Présenter les résultats de notre pratique et déterminer d’éventuelles spécificités
Matériels et méthode : Etude transversale descriptive sur 3 années, ayant inclus 93 patients. Examen réalisé sur un échographe GE Logic 8, par le même opérateur avec une aiguille 18 gauges montée sur un pistolet BARD system (selon les recommandations internationales) et les prélèvements acheminés dans les laboratoires d’anatomie pathologique.
Résultats : L’âge moyen des patients était de 63,18 ans ± 7,84 ans. Les principaux motifs de consultation étaient l’élévation des PSA (38,71 %) et l’hypertrophie prostatique (32,26 %). Le taux de PSA moyen était de 63,72ng/ml. Le volume prostatique moyen était de 68,55 cc. L’échographie avait montré une prostate hétérogène (95%) et des nodules (78%). Les nodules étaient hypo échogènes (78 %) et situées en zone périphérique (66%). Il existait une effraction capsulaire (56 %), un envahissement locorégional (11 %) et des adénomégalies (8,06 %). En moyenne 8,53 prélèvements biopsiques étaient effectués. Tous les patients avaient eu une anesthésie locale des bandelettes neurovasculaires à la lidocaïne injectable diluée à 2%. L’histologie montrait 45,16 % d’adénocarcinomes (âge moyen : 65,97 ans), un score de Gleason 7 et 9 (30,95 %), un engainement péri nerveux (16,67 %). Dans 51,72% des cas les carottes étaient positives à 90-100% et de façon bilatérales (60 %) avec une taille tumorale moyenne de 6 mm ± 4,01mm.
Conclusion : Notre étude a montré que le cancer de la prostate avait un score de Gleason et un volume tumorale élevés avec une proportion importante de carottes positives, prédictifs d’une maladie extra prostatique et d’un taux important de récidive tumorale.
Downloads
References
2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [29 09 2023].
3. Yacoub JH, Verma S, Moulton JS et al. Imaging-guided Prostate Biopsy: Conventional and Emerging Techniques. RadioGraphics 2012; 32: 810-37.
4. Ouzzane A, Coloby P, Mignard J-P et al. Guidelines for prostatic biopsies best practice. Progrès en urologie 2011; 21: 18-28.
5. Nazir B. Pain during Transrectal Ultrasound-Guided Prostate Biopsy and the Role of Periprostatic Nerve Block: What Radiologist Should Know. Korean J 2014; 15: 543-53.
6. Josephine A et al. Clinicopathological Study of Prostatic Biopsies. Journal of Clinical and Diagnostic Research 2014; 8: 4-6.
7. Harvey CJ, Pilcher J, Richenberg J, et al. Applications of transrectal ultrasound in prostate cancer. The British Journal of Radiology 2012; 85: S3-S17.
8. Catalona WJ, Richie JP, Ahjmann FR. Comparison of digital rectal examination and serum PSA in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-90.
9. Stamey TA. Making the most out of 6 systematic sextant biopsies. Urology 1995; 45: 2-12.
10. Terris MK, MacNeal JE, Stamey TA, et al. Transrectal ultrasound imaging and ultrasound guided prostate biopsies in the detection of residual carcinoma in clinical stage A carcinoma of the prostate. J Urol 1992; 147: 864-69.
11. Cornud F, Belin X, Fromont G. Imagerie de la prostate. Flammarion Medecine-Sciences 1993.
12. Toi A, Neill M, Lockwood G et al. the continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007; 177: 516-20.
13. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-74.
14. Scattoni V, Zlotta AR, Nava L, Roscigno M, et al. Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and TRUS prostatic lesion-guided biopsies. Eur Urol 2002; (Suppl 1): 28-34.
15. Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1603-12.
16. Bostwick DG, Quian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361-67.
17. Salomon L, Hoznek A, Lefrere-Belda MA et al. Value of biopsies in staging of prostate cancer radical prostatectomy. Progrès en Urologie 1998; 8: 969-76.
18. Parker ME. Gleason grading. Am J Surg Pathol 1995; 19: 852-54.
19. Spires SE, Cibull ML, Wood DP, et al. Gleason histologic grading in prostatic carcinoma: correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 1994; 118: 705-08.
20. Aihara M, Wheeler TM, Ohori M et al. Heterogeneity of prostate cancer in radical prostatectomy. J Urol 1993; 150: 1845-50.
21. Parkin DM,Ferlay J, Hamdi-Cherif M, et al. Cancer in Africa: epidemiology and prevention. Lyon: IARC Scientific Publications 200339-375.
22. Effi AB, N’dah KJ, N’guiessan AA et al. Epidémiologie et Histopathologie des cancers en Côte d’Ivoire. J. Afr cancer 2012; 4: 41-47.
23. Gleason DF. Histologic grading of prostate cancer: a perspective. Human Pathology 1992; 23: 273-79.
24. Fernandes ET, Sundaram CP, Long R, et al. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 1997; 79: 615-17.
25. Ravery V, Boccon-Gibod LA, Dauge-GeffroyMC, et al. Systematic biopsies accurately predict predict extracapsular extension of prostate cancer and persistent/ recurrent detectable PSA after radical prostatectomy. Urology 1994; 44: 371-76.
26. Ravery V, Boccon-Gibod LA, Dauge-GeffroyMC, et al. Place des critères biologiques et anatomopathologiques dans l’évaluation pronostique des patients avant et après prostatectomie radicale. Prog Urol 1994 ;4 : 673-82.
27. Ravery V, Linot O, Tobolski F, et al. Advances in the assessment of clinically localized prostate cancer. Eur Urol 1996; 29: 257-65.
28. Dunzinger M, Sega W, Madersbacher S, Schorn A. Predictive value of the anatomical location of ultrasound-guided systematic sextant prostate biopsies for the nodal status of patients with localized prostate cancer. Eur Urol 1997; 31: 317-22.
29. Guilloneau B, Debras B, Veillon B, et al. Indications for preoperative seminal vesicles biopsies in stadification of clinically localized prostatic cancer. Eur Urol 1997; 32: 160-65.
30. Daniels GF, MacNeal JE, Stamey TA, et al. Predictive value of controlateral biopsies in an unilaterally palpable prostate cancer. J Urol 1992; 147, 870-74.
31. Mittal BV, Amin MB, Kinare SG. Spectrum of histological lesions in 185 consecutive prostatic specimens. J Postgrad Med 1989; 35: 157.
32. Hashim U Ahmed, Ahmed El-Shater B, Louise C Brown et al. Diagnostic accuracy multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389: 815-22
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Copyright @2017. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted non-commercial used, distribution and reproduction in any medium